The TIGeR-PaC clinical trial is a study of Trans-Arterial Micro-Perfusion (TAMP™) for targeted delivery of chemotherapy to disease sites with a FDA cleared medical device system.
Location: United States, California, Los Altos
Employees: 1-10
Phone: +1 650-284-4433
Total raised: $11.15M
Founded date: 2009
Investors 5
| Date | Name | Website |
| - | SV Tech Ve... | svtechvent... |
| - | Astia Ange... | astia.org |
| - | Plug and P... | plugandpla... |
| 01.12.2024 | SeedFolio | seedfolio.... |
| - | StartX | startx.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.05.2018 | - | $10M | - |
| 28.01.2014 | Series B | $1.15M | - |
Mentions in press and media 12
| Date | Title | Description |
| 20.07.2023 | RenovoRx and Imugene Announce plans to Deliver Oncolytic Virus Therapy Using Trans-Arterial Micro-Perfusion Platform. | Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. (NASDAQ:RNXT) Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline f... |
| 20.12.2022 | xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study | RenovoRx's Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life. Our therapy platform is challenging the standard-of-care treatment available to local... |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| 16.11.2021 | RenovoRx : Announces Third Quarter 2021 Financial Results - Form 8-K | RenovoRx Announces Third Quarter 2021 Financial Results Los Altos, CA, November 15, 2021 - RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today reported its unaudited financial results f... |
| 07.09.2021 | RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors | |
| 25.08.2021 | RenovoRx Announces Pricing of Initial Public Offering | |
| 20.01.2021 | RenovoRx Announces Studies that Further Advance the Science of Pancreatic Cancer Treatment Presented at the 2021 ASCO Gastrointestinal Cancers Symposium | |
| 23.05.2018 | Boston Scientific Leads $10M Funding for RenovoRx | LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc., a medical technology company developing an innovative catheter-based approach to treating pancreatic cancer, today announced a $10 million financing round of which the company closed $7 mi... |
| 23.05.2018 | RenovoRx Raises $10M in Financing | RenovoRx, Inc., a Los Altos, Calif.-based medical technology company developing an innovative catheter-based approach to treating pancreatic cancer, raised $10m in financing. The round was led by Boston Scientific with participation from ne... |
| 23.05.2018 | Term Sheet — Wednesday, May 23 | 5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop “When I looked around, I saw a lot of women who were starting businesses,” she told Term Sheet. “I recognized that in the... |
Show more